Overview of the latest treatments for castration-resistant prostate cancer.
about
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancerCirculating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.The role of GATA2 in lethal prostate cancer aggressiveness.Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastasesScreening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.Androgen receptor: structure, role in prostate cancer and drug discovery.Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.Opportunities and challenges in combination gene cancer therapy.Bone-Targeted Imaging and Radionuclide Therapy in Prostate CancerAilanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer.Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancerIdentification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancerAR function in promoting metastatic prostate cancerNutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells.Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer ProgressionDevelopment and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.Antagonizing the Androgen Receptor with a Biomimetic Acyltransferase.Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression.Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes.Role of 20-Hydroxyeicosatetraenoic Acid (20-HETE) in Androgen-Mediated Cell Viability in Prostate Cancer Cells.Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.
P2860
Q27853127-610CDB5D-7237-473D-B8F5-FFCA99B7EBFCQ33613644-A5D7722E-EF93-4C09-8E5D-C1B99D7A82A2Q33848134-BDE02618-2CDC-41FD-ACCC-F6A6169005A0Q34132305-F1940235-8BED-4754-B93A-1A64A96C0180Q35554014-6689AEDD-913C-41BE-AFFC-9DE69972200DQ35603660-5FB8333A-4F2F-4203-8A2B-E61038620A1FQ36063723-724C4395-F1E6-42FC-9375-B4C6459813B2Q36823062-07C558AA-8318-4058-A2CA-708F01C4206EQ37118663-94EA9EFB-D8C2-4819-A423-0489069458DFQ37390666-88471155-E397-4327-BAEA-7F52DA094761Q37508596-E6A76AAE-56F0-45BF-9C6A-D547BCE5AE7DQ37645051-9C6A8A8E-83EB-4030-AB49-33ED903C1405Q37718438-68C1A254-F244-4639-BB03-08D2977E1A92Q38178555-A34B0B8F-4471-4701-908B-B84F5CDFC4E5Q38812632-675CAAA4-0565-498F-A8C0-00A702B02C0DQ38820055-097765B7-F763-4074-B4A5-D2FEEA9EF2DEQ38844202-C8305DC6-73C2-4472-AA18-280FF2661598Q38970758-F2242416-E110-49AF-9554-2797508A4E8FQ39467130-FD8F6AD9-0C08-4040-AFFA-B4F94124E75AQ41382610-E508D6BB-B2BA-40C2-9A1D-69C96EF78638Q42282866-E7C57DAC-3161-4E73-87E6-020FD45926CFQ45988720-AD01A774-360B-458A-B56B-844451F0BD12Q48238746-E66B52E5-78E8-4068-848E-10242FA38B1BQ50852820-E8D5495D-2493-4B72-9AAF-E309DF18AD5AQ55398521-0B695ACD-AC88-41B2-85FD-C551CC5E3BAE
P2860
Overview of the latest treatments for castration-resistant prostate cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Overview of the latest treatments for castration-resistant prostate cancer.
@en
type
label
Overview of the latest treatments for castration-resistant prostate cancer.
@en
prefLabel
Overview of the latest treatments for castration-resistant prostate cancer.
@en
P2860
P356
P1476
Overview of the latest treatments for castration-resistant prostate cancer.
@en
P2093
Mohamed Bishr
P2860
P2888
P304
P356
10.1038/NRUROL.2013.137
P407
P577
2013-06-25T00:00:00Z
P6179
1040788782